


Cefpiramide

Cat. No.:	HY-B1354
CAS No.:	70797-11-4
Molecular Formula:	C ₂₅ H ₂₄ N ₈ O ₇ S ₂
Molecular Weight:	612.64
Target:	Bacterial; Antibiotic; Beta-lactamase
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cefpiramide (SM-1652) free acid is a semisynthetic cephalosporin with broad-spectrum antibacterial activity. Cefpiramide free acid shows strong antibacterial effect on both gram-positive bacteria and gram-negative bacteria. Cefpiramide free acid is moderately susceptible to β-lactamase ^{[1][2]} .								
IC₅₀ & Target	β-lactam								
In Vitro	<p>Cefpiramide (0-2048 μg/mL; 16-18 hours) shows good activity to against most non-fermentative Gram-negative bacilli and Enterococci (32 μg/mL with 97% inhibition)^[1].</p> <p>Cefpiramide (0-2048 μg/mL; 16-18 hours) exhibits high effective to against Pseudomonas aeruginosa with MIC_[50] and MIC_[90] values of 4 μg/mL and 16 μg/mL separately^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>761 bacterial isolates (35 different species of common bacterial pathogens)</td> </tr> <tr> <td>Concentration:</td> <td>0-2048 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>16-18 hours</td> </tr> <tr> <td>Result:</td> <td>Showed broad-spectrum antibacterial activity.</td> </tr> </table>	Cell Line:	761 bacterial isolates (35 different species of common bacterial pathogens)	Concentration:	0-2048 μg/mL	Incubation Time:	16-18 hours	Result:	Showed broad-spectrum antibacterial activity.
Cell Line:	761 bacterial isolates (35 different species of common bacterial pathogens)								
Concentration:	0-2048 μg/mL								
Incubation Time:	16-18 hours								
Result:	Showed broad-spectrum antibacterial activity.								
In Vivo	<p>Cefpiramide (25 mg/kg; i.v.; once) shows anti-Streptococcus pneumoniae activity in experimental pneumococcal meningitis^[2].</p> <p>Cefpiramide (25 mg/kg; i.v.; once) reduces bacteria in CSF more than 10^[4] CFU/ml^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>New Zealand white male rabbits(2-3 kg)^[2].</td> </tr> <tr> <td>Dosage:</td> <td>25 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; once.</td> </tr> <tr> <td>Result:</td> <td>Anti-Streptococcus pneumoniae.</td> </tr> </table>	Animal Model:	New Zealand white male rabbits(2-3 kg) ^[2] .	Dosage:	25 mg/kg	Administration:	Intravenous injection; once.	Result:	Anti-Streptococcus pneumoniae.
Animal Model:	New Zealand white male rabbits(2-3 kg) ^[2] .								
Dosage:	25 mg/kg								
Administration:	Intravenous injection; once.								
Result:	Anti-Streptococcus pneumoniae.								

REFERENCES

[1]. Barry AL, et al. Cefpiramide: comparative in-vitro activity and beta-lactamase stability. J Antimicrob Chemother. 1985 Sep;16(3):315-25.

[2]. Sato K, et al. Pharmacokinetics and bacteriological efficacies of apalcillin and cefpiramide in experimental pneumococcal meningitis. Antimicrob Agents Chemother. 1984 Oct;26(4):578-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA